H. Douagui

Centre Hospitalo-Universitaire Bab El Oued

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

СБ

С. Бонини

Istituto di Farmacologia Traslazionale

Piotr Kuna

Medical University of Lodz

Marc Humbert

Hôpital Marie Lannelongue

Claus Bachert

Ghent University Hospital

P. Démoly

Université de Montpellier

AČ

Adnan Čustović

Imperial College London

João Fonseca

Universidade do Porto

Torsten Zuberbier

Charité - Universitätsmedizin Berlin

Giorgio Walter Canonica

Humanitas University

Osman Yusuf

Institute for Asthma and Allergy

Cooperative Institutions

University of Debrecen

147

The Geneva Association

147

New York Proton Center

141

World Health Organization - Pakistan

132

Municipal Institute for Medical Research

Hospital Del Mar

Centre Hospitalier Universitaire de Montpellier

Charité - Universitätsmedizin Berlin

Inserm

University of Helsinki

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Integrated care pathways for airway diseases (AIRWAYS-ICPs)

European Respiratory Journal (2014)

Jean Bousquet Antonio Addis Ian M. Adcock Ioana Agache Àlvar Agustí

The objective of Integrated Care Pathways for Airway Diseases (AIRWAYS-ICPs) is to launch a collaboration to develop multi-sectoral care pathways for chronic respiratory diseases in European countries and regions.AIRWAYS-ICPs has strategic relevance to the European Union Health Strategy and will add value to existing public health knowledge by: 1) proposing a common framework of care pathways for chronic respiratory diseases, which will facilitate comparability and trans-national initiatives; 2) informing cost-effective policy development, strengthening in particular those on smoking and environmental exposure; 3) aiding risk stratification in chronic disease patients, using a common strategy; 4) having a significant impact on the health of citizens in the short term (reduction of morbidity, improvement of education in children and of work in adults) and in the long-term (healthy ageing); 5) proposing a common simulation tool to assist physicians; and 6) ultimately reducing the healthcare burden (emergency visits, avoidable hospitalisations, disability and costs) while improving quality of life.In the longer term, the incidence of disease may be reduced by innovative prevention strategies.AIRWAYS-ICPs was initiated by Area 5 of the Action Plan B3 of the European Innovation Partnership on Active and Healthy Ageing.All stakeholders are involved (health and social care, patients, and policy makers).@ERSpublications AIRWAYS-ICPs: launch of a collaboration to develop multi-sectoral integrated care pathways for respiratory disease

Action plan

10.1183/09031936.00014614

Cite

Citations (165)

MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis)

Jean Bousquet Holger J. Schünemann João Fonseca B Samoliński Claus Bachert

Several unmet needs have been identified in allergic rhinitis: identification of the time of onset of the pollen season, optimal control of rhinitis and comorbidities, patient stratification, multidisciplinary team for integrated care pathways, innovation in clinical trials and, above all, patient empowerment. MASK-rhinitis (MACVIA-ARIA Sentinel NetworK for allergic rhinitis) is a simple system centred around the patient which was devised to fill many of these gaps using Information and Communications Technology (ICT) tools and a clinical decision support system (CDSS) based on the most widely used guideline in allergic rhinitis and its asthma comorbidity (ARIA 2015 revision). It is one of the implementation systems of Action Plan B3 of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA). Three tools are used for the electronic monitoring of allergic diseases: a cell phone-based daily visual analogue scale (VAS) assessment of disease control, CARAT (Control of Allergic Rhinitis and Asthma Test) and e-Allergy screening (premedical system of early diagnosis of allergy and asthma based on online tools). These tools are combined with a clinical decision support system (CDSS) and are available in many languages. An e-CRF and an e-learning tool complete MASK. MASK is flexible and other tools can be added. It appears to be an advanced, global and integrated ICT answer for many unmet needs in allergic diseases which will improve policies and standards.

Action plan

Source

Cite

Citations (0)

Erratum to: Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)

Clinical and Translational Allergy (2017)

Jean Bousquet J. Farrell G. Crooks Peter W. Hellings Elisabeth H. Bel

Action plan

Healthy ageing

10.1186/s13601-016-0135-6

Cite

Citations (8)

Table of Contents

Journal of Allergy and Clinical Immunology (2012)

Marc E. Rothenberg Jean Bousquet Patricia C. Fulkerson La ́szlo ́maro ́di Sophie Cypowyj

Table (database)

10.1016/s0091-6749(12)01560-6

Cite

Citations (0)

MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation

Allergy (2015)

Jean Bousquet Holger J. Schünemann João Fonseca Bolesław Samoliński Claus Bachert

Guideline

Action plan

Allergic conjunctivitis

10.1111/all.12686

Cite

Citations (191)

Allergie au miel : diagnostic et prise en charge

W. Saidji N. Bencharif M. Gharnaout H. Douagui

Source

Cite

Citations (0)

ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle

Clinical and Translational Allergy (2016)

Jean Bousquet Peter W. Hellings Ioana Agache Anna Bedbrook Claus Bachert

The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization workshop in 1999. The initial goals were (1) to propose a new allergic rhinitis classification, (2) to promote the concept of multi-morbidity in asthma and rhinitis and (3) to develop guidelines with all stakeholders that could be used globally for all countries and populations. ARIA—disseminated and implemented in over 70 countries globally—is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK [MACVIA (Contre les Maladies Chroniques pour un Vieillissement Actif)-ARIA Sentinel NetworK] uses mobile technology to develop care pathways for the management of rhinitis and asthma by a multi-disciplinary group and by patients themselves. An app (Android and iOS) is available in 20 countries and 15 languages. It uses a visual analogue scale to assess symptom control and work productivity as well as a clinical decision support system. It is associated with an inter-operable tablet for physicians and other health care professionals. The scaling up strategy uses the recommendations of the European Innovation Partnership on Active and Healthy Ageing. The aim of the novel ARIA approach is to provide an active and healthy life to rhinitis sufferers, whatever their age, sex or socio-economic status, in order to reduce health and social inequalities incurred by the disease.

10.1186/s13601-016-0137-4

Cite

Citations (147)

Integrated care pathways for airway diseases (AIRWAYS-ICPs) European Innovation Partnership on Active and Healthy Ageing, Action Plan B3 Mechanisms of the Development of Allergy (MeDALL, WP10) GARD (Global Alliance against Chronic Respiratory Diseases, WHO) research demonstration project

Jean Bousquet Antonio Addis Ian M. Adcock Ioana Agache Àlvar Agustí

The objective of Integrated Care Pathways for Airway Diseases (AIRWAYS-ICPs) is to launch a collaboration to develop multi-sector care pathways for chronic respiratory diseases in European countries and regions. AIRWAYS-ICPs has strategic relevance to the European Union Health Strategy and will add value to existing public health knowledge by: 1) proposing a common framework of care pathways for chronic respiratory diseases, which will facilitate comparability and trans-national initiatives; 2) informing cost-effective policy development, strengthening in particular those on smoking and environment exposure; 3) aiding risk stratification in chronic disease patients, using a common strategy; 4) having a significant impact on the health of citizens in the short term (reduction of morbidity, improvement of education in children and of work in adults) and in the long-term (healthy ageing); 5) proposing a common simulation tool to assist physicians; and 6) ultimately reducing the healthcare burden (emergency visits, avoidable hospitalisations, disability and costs) while improving quality of life. In the longer term, the incidence of disease may be reduced by innovative prevention strategies. AIRWAYS-ICPs was initiated by Area 5 of the Action Plan B3 of the European Innovative Partnership on Active and Healthy Ageing. All stakeholders are involved (health and social care, patients, and policy makers). European Respiratory Journal erj00146-2014.3d 17/4/14 10:01:30 The Charlesworth Group, Wakefield +44(0)1924 369598 Rev 7.51n/W (Jan 2

Action plan

Source

Cite

Citations (8)

Severe Chronic Allergic (and Related) Diseases: A Uniform Approach – A MeDALL – GA<sup>2</sup>LEN – ARIA Position Paper

International Archives of Allergy and Immunology (2012)

Jean Bousquet J. M. Antó P. Démoly Holger J. Schünemann Alkis Togias

Concepts of disease severity, activity, control and responsiveness to treatment are linked but different. Severity refers to the loss of function of the organs induced by the disease process or to the occurrence of severe acute exacerbations. Severity may vary over time and needs regular follow-up. Control is the degree to which therapy goals are currently met. These concepts have evolved over time for asthma in guidelines, task forces or consensus meetings. The aim of this paper is to generalize the approach of the uniform definition of severe asthma presented to WHO for chronic allergic and associated diseases (rhinitis, chronic rhinosinusitis, chronic urticaria and atopic dermatitis) in order to have a uniform definition of severity, control and risk, usable in most situations. It is based on the appropriate diagnosis, availability and accessibility of treatments, treatment responsiveness and associated factors such as comorbidities and risk factors. This uniform definition will allow a better definition of the phenotypes of severe allergic (and related) diseases for clinical practice, research (including epidemiology), public health purposes, education and the discovery of novel therapies.

Chronic Rhinosinusitis

Omalizumab

10.1159/000332924

Cite

Citations (92)

European Innovation Partnership on Active and Healthy Ageing, Action Plan B3 Mechanisms of the Development of Allergy (MeDALL, WP10) GARD (Global Alliance against Chronic Respiratory Diseases, WHO) research demonstration project

Claus Bachert Chunxue Bai Cristina Bárbara L. Beck Anna Bedbrook

Action plan

Healthy ageing

Source

Cite

Citations (1)